Physician profile
William J Sciortino
NPI 1831202274
$3,408.83
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $325 · 2021: $208 · 2022: $396 · 2023: $256 · 2024: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,590.17 | 2019-2024 | Rocklatan, Rhopressa, Simbrinza |
| Allergan, INC. | $442.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $346.09 | 2019-2023 | |
| Horizon Therapeutics Plc | $225.15 | 2019-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $156.08 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $151.87 | 2019-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $142.19 | 2022 | |
| Bausch & Lomb Americas INC. | $120.60 | 2023-2024 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.58 | 2019 | |
| Oyster Point Pharma, INC. | $26.23 | 2022 | |
| Abbvie INC. | $22.93 | 2023 | Lumigan, Alphagan P |
| Astellas Pharma US INC | $22.27 | 2023 | |
| Omeros Corporation | $19.67 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.89 | 2022 | |
| Spark Therapeutics, INC. | $13.57 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sciortino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.